Ticalor Adverse Reactions

The safety of ticagrelor in patients with acute coronary syndromes (UA, NSTMI and STEMI) was evaluated in a single large phase 3 study (PLATO [Platelet Inhibition and Patient Outcomes] study) which compared patients treated with ticagrelor (loading dose of 180 mg of ticagrelor and a maintenance dose of 90 mg bid) to patients treated with clopidogrel (300-600 mg loading dose followed by 75 mg once daily maintenance dose) both given in combination with acetylsalicylic acid (aspirin) and other standard therapies.
The most commonly reported adverse events in patients treated with ticagrelor were bleedings and dyspnoea and these events occurred at higher rates than in the clopidogrel treatment group. During the treatment period, the ticagrelor group had a higher incidence of discontinuation due to adverse events than clopidogrel (7.4% vs 5.4%).
Adverse reactions are classified according to frequency and System Organ Class (SOC). Frequency categories are defined according to the following conventions: Very common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); Rare (≥1/10,000, <1/1,000); Very rare (≥1/10,000, <1/1,000). (See table.)

Click on icon to see table/diagram/image